EXCLUSIVE OPTION AGREEMENT for MSK’s technology EBV/CMV and WT1 specific T-cellsExclusive Option Agreement • May 11th, 2015 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Exclusive Option Agreement (“Agreement”), effective as of September 19, 2014 (“Effective Date”), is made by and between MEMORIAL SLOAN KETTERING CANCER CENTER (“MSK”), a New York membership corporation with principal offices at 1275 York Avenue, New York, New York 10065, and ATARA BIOTHERAPEUTICS, INC. (“COMPANY”), a corporation with offices at 3260 Bayshore Blvd., Brisbane, CA 94005. MSK and COMPANY are sometimes referred to singly as “Party” and collectively as “Parties”.
